C4 Therapeutics, Inc. (NASDAQ:CCCC – Get Free Report) CFO Kendra Adams sold 45,173 shares of C4 Therapeutics stock in a transaction dated Thursday, November 12th. The shares were sold at an average price of $2.71, for a total transaction of $122,418.83. Following the sale, the chief financial officer owned 337,150 shares in the company, valued at approximately $913,676.50. This trade represents a 11.82% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
C4 Therapeutics Trading Down 0.4%
NASDAQ CCCC traded down $0.01 on Friday, reaching $2.76. The company’s stock had a trading volume of 2,543,578 shares, compared to its average volume of 3,051,738. C4 Therapeutics, Inc. has a 52 week low of $1.69 and a 52 week high of $5.17. The firm has a market cap of $362.44 million, a PE ratio of -3.83 and a beta of 3.16. The business has a 50-day moving average price of $3.13 and a 200 day moving average price of $3.24.
C4 Therapeutics (NASDAQ:CCCC – Get Free Report) last announced its quarterly earnings results on Thursday, November 5th. The company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.03. The firm had revenue of $8.47 million during the quarter, compared to analysts’ expectations of $8.52 million. C4 Therapeutics had a negative net margin of 282.22% and a negative return on equity of 37.71%. Analysts anticipate that C4 Therapeutics, Inc. will post -0.73 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A number of institutional investors have recently modified their holdings of CCCC. CDC Financial Inc. boosted its holdings in shares of C4 Therapeutics by 6,710.5% in the 3rd quarter. CDC Financial Inc. now owns 68,105 shares of the company’s stock worth $227,000 after acquiring an additional 67,105 shares in the last quarter. Jump Financial LLC grew its position in C4 Therapeutics by 8.2% during the 3rd quarter. Jump Financial LLC now owns 197,641 shares of the company’s stock worth $658,000 after acquiring an additional 14,941 shares during the last quarter. Marshall Wace LLP grew its position in C4 Therapeutics by 277.0% during the 3rd quarter. Marshall Wace LLP now owns 855,805 shares of the company’s stock worth $2,850,000 after acquiring an additional 628,802 shares during the last quarter. Empowered Funds LLC acquired a new stake in C4 Therapeutics during the 3rd quarter valued at $229,000. Finally, Russell Investments Group Ltd. increased its holdings in C4 Therapeutics by 170.5% during the 3rd quarter. Russell Investments Group Ltd. now owns 21,924 shares of the company’s stock valued at $73,000 after purchasing an additional 13,819 shares in the last quarter. Institutional investors own 78.81% of the company’s stock.
Analyst Upgrades and Downgrades
A number of equities analysts have recently issued reports on the company. JPMorgan Chase & Co. began coverage on C4 Therapeutics in a report on Friday, October 9th. They issued an “overweight” rating and a $10.00 target price for the company. Guggenheim started coverage on C4 Therapeutics in a research note on Friday, November 6th. They issued a “buy” rating and a $6.00 price target on the stock. Lake Street Capital assumed coverage on C4 Therapeutics in a research report on Wednesday, October 28th. They issued a “buy” rating and a $11.00 price target on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of C4 Therapeutics in a research note on Thursday, October 15th. Finally, Evercore lowered C4 Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 2nd. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $8.50.
Read Our Latest Stock Analysis on CCCC
About C4 Therapeutics
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Watertown, Massachusetts. Founded in 2015, it develops medicines designed to selectively remove disease-causing proteins, with a focus on cancer. The company uses its TORPEDO platform to design targeted protein degraders. These molecules are intended to bind a target protein and recruit the cell’s natural protein-disposal machinery, leading to the protein’s breakdown. C4 Therapeutics’ research and development programs include oral small-molecule candidates for oncology.
Featured Articles
- Five stocks we like better than C4 Therapeutics
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for C4 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C4 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
